Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Feb;39(2):161–167. doi: 10.1111/j.1365-2125.1995.tb04423.x

Pharmacokinetics and pharmacodynamics of roxatidine in patients with renal insufficiency.

U Gladziwa 1, S Wagner 1, H G Sieberth 1, U Klotz 1
PMCID: PMC1364953  PMID: 7742154

Abstract

1. Roxatidine acetate, a new histamine H2-receptor antagonist, was administered in the evening (75 mg p.o.) to eight patients with renal insufficiency (CLCR 8-17 ml min-1) for 12 days and plasma drug concentrations were measured. 2. Ambulatory intragastric pH was monitored following the last dose and values were compared with those on day 1 when all patients received a placebo. 3. The terminal elimination half-life (mean +/- s.d.) of roxatidine was 10.8 +/- 2.4 h and its oral clearance was 178 +/- 43 ml min-1. 4. During roxatidine treatment gastrin levels increased slightly (median 189 vs 289 ng l-1) and the hyperparathyroid status of the patients was almost normalized (parathyroid hormone levels: median 199 vs 132 ng l-1). 5. The mean latency to a gastric pH of at least 4 was 4.3 +/- 1.4 h. The duration of action (intragastric pH > 4) was 10.6 +/- 3.9 h. 6. As in a pilot study with six patients (CLCR < or = 17 ml min-1) the recommended dosage regimen (75 mg 48 h-1) was unable to maintain gastric pH > 4 for more than 6 h, daily nocturnal intake of 75 mg roxatidine acetate appears appropriate to elevate gastric pH > 4 for a sufficient period of time.

Full text

PDF
161

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala-Kaila K., Kekki M., Paronen I., Paakkala T. Serum gastrin in chronic renal failure: its relation to acid secretion, G-cell density, and upper gastrointestinal findings. Scand J Gastroenterol. 1989 Oct;24(8):939–948. doi: 10.3109/00365528909089238. [DOI] [PubMed] [Google Scholar]
  2. Ala-Kaila K. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol. 1987 Apr;22(3):372–376. doi: 10.3109/00365528709078607. [DOI] [PubMed] [Google Scholar]
  3. Burrows J. L., Jolley K. W., Sullivan D. J. Determination of roxatidine in human plasma, urine and milk by capillary gas chromatography using nitrogen-selective detection. J Chromatogr. 1988 Nov 18;432:199–208. doi: 10.1016/s0378-4347(00)80645-3. [DOI] [PubMed] [Google Scholar]
  4. Collins J. D., Pidgen A. W. Pharmacokinetics of roxatidine in healthy volunteers. Drugs. 1988;35 (Suppl 3):41–47. doi: 10.2165/00003495-198800353-00009. [DOI] [PubMed] [Google Scholar]
  5. Festen H. P., Thijs J. C., Lamers C. B., Jansen J. M., Pals G., Frants R. R., Défize J., Meuwissen S. G. Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels. Gastroenterology. 1984 Nov;87(5):1030–1034. [PubMed] [Google Scholar]
  6. Gladziwa U., Bares R., Klotz U., Dakshinamurty K. V., Ittel T. H., Seiler K. U., Sieberth H. G. Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clin Pharmacol Ther. 1991 Dec;50(6):673–681. doi: 10.1038/clpt.1991.206. [DOI] [PubMed] [Google Scholar]
  7. Gladziwa U., Ittel T. H., Dakshinamurty K. V., Schacht B., Riehl J., Sieberth H. G. Secondary hyperparathyroidism and sonographic evaluation of parathyroid gland hyperplasia in dialysis patients. Clin Nephrol. 1992 Sep;38(3):162–166. [PubMed] [Google Scholar]
  8. Gladziwa U., Klotz U., Krishna D. R., Schmitt H., Glöckner W. M., Mann H. Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol. 1988 Sep;26(3):315–321. doi: 10.1111/j.1365-2125.1988.tb05282.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gladziwa U., Klotz U. Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency. Clin Pharmacokinet. 1993 Apr;24(4):319–332. doi: 10.2165/00003088-199324040-00005. [DOI] [PubMed] [Google Scholar]
  10. Gladziwa U., Wagner S., Dakshinamurty K. V., Bechtel B., Mann H., Sieberth H. G. Intragastric long-term pH-metry in hemodialysis patients. A study with famotidine. Clin Nephrol. 1991 Aug;36(2):97–102. [PubMed] [Google Scholar]
  11. Gladziwa U., Wagner S., Dakshinamurty K. V., el Desoky E., Dreuw B., Klotz U. Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis. Eur J Clin Pharmacol. 1993;44(4):357–360. doi: 10.1007/BF00316472. [DOI] [PubMed] [Google Scholar]
  12. Gladziwa U., Wagner S., Kock R., Mann H., Sieberth H. G. Sonographic evaluation of gallbladder motility in patients with end-stage renal disease on haemodialysis. Nephrol Dial Transplant. 1992;7(8):840–843. [PubMed] [Google Scholar]
  13. Inoue M. Clinical studies on the use of roxatidine acetate for the treatment of peptic ulcer in Japan. Drugs. 1988;35 (Suppl 3):114–119. doi: 10.2165/00003495-198800353-00020. [DOI] [PubMed] [Google Scholar]
  14. Jacob A. I., Lanier D., Jr, Canterbury J., Bourgoignie J. J. Reduction by cimetidine of serum parathyroid hormone levels in uremic patients. N Engl J Med. 1980 Mar 20;302(12):671–674. doi: 10.1056/NEJM198003203021207. [DOI] [PubMed] [Google Scholar]
  15. Korman M. G., Laver M. C., Hansky J. Hypergastrinaemia in chronic renal failure. Br Med J. 1972 Jan 22;1(5794):209–210. doi: 10.1136/bmj.1.5794.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lameire N., Rosenkranz B., Brockmeier D. Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure. Scand J Gastroenterol Suppl. 1988;146:100–110. doi: 10.3109/00365528809099136. [DOI] [PubMed] [Google Scholar]
  17. Lameire N., Rosenkranz B., Maass L., Brockmeier D. A pharmacokinetic study of roxatidine acetate in chronic renal failure. Drugs. 1988;35 (Suppl 3):48–52. doi: 10.2165/00003495-198800353-00010. [DOI] [PubMed] [Google Scholar]
  18. Lassman H. B., Ho I., Puri S. K., Sabo R., Scheffler M. R. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men. Drugs. 1988;35 (Suppl 3):53–64. doi: 10.2165/00003495-198800353-00011. [DOI] [PubMed] [Google Scholar]
  19. Makdassi R., Decourcelle P. H., Moriniere P., Coevoet B., de Fremont J. F., Kassouf J., Roussel A., Gheerbrand J. D., Andrejak M., Fournier A. Blockers of beta and H2 receptors and secondary hyperparathyroidism in uraemia. Proc Eur Dial Transplant Assoc. 1981;18:642–647. [PubMed] [Google Scholar]
  20. Martyn J. A., Bishop A. L., Oliveri M. F. Pharmacokinetics and pharmacodynamics of ranitidine after burn injury. Clin Pharmacol Ther. 1992 Apr;51(4):408–414. doi: 10.1038/clpt.1992.40. [DOI] [PubMed] [Google Scholar]
  21. Merki H. S., Witzel L., Kaufmann D., Kempf M., Neumann J., Scheurle E., Röhmel J., Walt R. P. The effects of roxatidine acetate on 24-hour intragastric acidity. Investigations in healthy volunteers and comparison with ranitidine and placebo. Drugs. 1988;35 (Suppl 3):69–75. doi: 10.2165/00003495-198800353-00013. [DOI] [PubMed] [Google Scholar]
  22. Milito G., Taccone-Gallucci M., Brancaleone C., Nardi F., Filingeri V., Cesca D., Casciani C. U. Assessment of the upper gastrointestinal tract in hemodialysis patients awaiting renal transplantation. Am J Gastroenterol. 1983 Jun;78(6):328–331. [PubMed] [Google Scholar]
  23. Mohammed R., Holden R. J., Hearns J. B., McKibben B. M., Buchanan K. D., Crean G. P. Effects of eight weeks' continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion, and fasting serum gastrin. Gut. 1983 Jan;24(1):61–66. doi: 10.1136/gut.24.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Palmer F. J., Sawyers T. M., Wierzbinski S. J. Cimetidine and hyperparathyroidism. N Engl J Med. 1980 Mar 20;302(12):692–692. doi: 10.1056/NEJM198003203021216. [DOI] [PubMed] [Google Scholar]
  25. Pozet N., Labeeuw M., Hadj Aissa A., Bizolon C., Zech P., Traeger J. Effects of acute and chronic ranitidine administration on renal function and parathyroid activity in chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:761–764. [PubMed] [Google Scholar]
  26. Shepherd A. M., Stewart W. K., Wormsley K. G. Peptic ulceration in chronic renal failure. Lancet. 1973 Jun 16;1(7816):1357–1359. doi: 10.1016/s0140-6736(73)91677-2. [DOI] [PubMed] [Google Scholar]
  27. Sherwood J. K., Ackroyd F. W., Garcia M. Effect of cimetidine on circulating parathyroid hormone in primary hyperparathyroidism. Lancet. 1980 Mar 22;1(8169):616–620. doi: 10.1016/s0140-6736(80)91117-4. [DOI] [PubMed] [Google Scholar]
  28. Takabatake T., Ohta H., Yamamoto Y., Ishida Y., Hara H., Nakamura S., Ushiogi Y., Satoh S., Hattori N. Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function. Eur J Clin Pharmacol. 1986;30(6):709–712. doi: 10.1007/BF00608220. [DOI] [PubMed] [Google Scholar]
  29. Wagner S., Gladziwa U., Gebel M., Schüler A., Freise J., Schmidt F. W. Circadian pattern of intragastric acidity in duodenal ulcer patients: a study of variations in relation to ulcer activity. Gut. 1991 Oct;32(10):1104–1109. doi: 10.1136/gut.32.10.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES